|
|
||||||||
Ann Thorac Surg 2001;71:397
© 2001 The Society of Thoracic Surgeons
a Division of Cardiology, George Washington University Medical Center, 2150 Pennsylvania Ave, NW, Washington, DC 20037, USA
To the Editor
I read with interest the case report of cardiac allograft valvulopathy from a donor with antemortem use of fenfluramine-phentermine for the preceding 8 months [1]. Despite removal of the heart from the causative environment, the allograft valvulopathy progressed. This case is contrary to the recent reports that dexfenfluramine-induced valvulopathy may regress after cessation of its use [2, 3]. Does it mean that the mitral valve in a transplanted, and therefore denervated, heart reacts differently from a native valve to cessation of the use of fenfluramine-phentermine?
References
Related Article
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |